Thousands more NHS patients with a deadly type of lung cancer are to benefit from a drug hailed as the biggest treatment breakthrough in decades. Sotorasib is a daily tablet that has been proved to shrink tumours in half of patients with advanced lung cancers not caused by smoking. This type, which affects one in eight lung-cancer sufferers, is caused by a mutation in a gene known as KRAS. It is a particularly lethal form of cancer for which current treatments are effective in only about ten per cent of sufferers. In a healthy body, the KRAS gene controls proteins that play a part in normal cell growth. But mutated KRAS genes allow the proteins to instruct cells to grow out of control, causi... [Read more]